Development of solid lipid nanoparticles of rivastigmine tartrate by using full factorial design for the treatment of alzheimer’s disease

Back ground Study: Solid lipid nanoparticles are attracting importance from drug developers due to their performance, ease of use, flexibility and their potential to produce intellectual property through innovation in drug delivery particularly in the case of modifying drug release systems. Objective: The objective of present investigation was to develop Rivastigmine Tartrate Solid lipid nanoparticles (SLN) by using full factorial design. Materials and Methods: The formulations were designed by Design-Expert software. A series of solid lipid nanoparticles (SLN) were prepared by modified solvent emulsification technique using lipid, surfactant, permeation enhancer and other solvents. SLN were evaluated for zeta potential, particle size, polydiispersity index, surface morphology by scanning electron microscopy (SEM) and in vitro drug release studies. Result and Discussion: The particle size of SLN was found in the range of 222±21 to 414±11 nm. Zeta potential of optimized formulation was found in the range of 31.74 ± 3.1 mV indicating stable formulation. SEM photographs indicate discrete spherical structure without any aggregation. Entrapment efficiency was found to be 57.28±1.7%. Conclusion: The results highlights that the prepared formulation of SLN were able to deliver a constant supply of the active pharmaceutical ingredient (API).